Recordati Industria Chimica e Farmaceutica SpA
MIL:REC

Watchlist Manager
Recordati Industria Chimica e Farmaceutica SpA Logo
Recordati Industria Chimica e Farmaceutica SpA
MIL:REC
Watchlist
Price: 46.3 EUR 0.65% Market Closed
Market Cap: €9.7B

Net Margin

16.4%
Current
Declining
by 1.4%
vs 3-y average of 17.8%

Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.

Net Margin
16.4%
=
Net Income
€407.3m
/
Revenue
€2.5B

Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.

Net Margin
16.4%
=
Net Income
€407.3m
/
Revenue
€2.5B

Peer Comparison

Country Company Market Cap Net
Margin
IT
Recordati Industria Chimica e Farmaceutica SpA
MIL:REC
9.5B EUR
Loading...
US
Eli Lilly and Co
NYSE:LLY
969.6B USD
Loading...
US
Johnson & Johnson
NYSE:JNJ
547.3B USD
Loading...
CH
Roche Holding AG
SIX:ROG
277.1B CHF
Loading...
UK
AstraZeneca PLC
LSE:AZN
209.4B GBP
Loading...
CH
Novartis AG
SIX:NOVN
219B CHF
Loading...
US
Merck & Co Inc
NYSE:MRK
271.3B USD
Loading...
DK
Novo Nordisk A/S
CSE:NOVO B
1.7T DKK
Loading...
IE
Endo International PLC
LSE:0Y5F
218B USD
Loading...
US
Pfizer Inc
NYSE:PFE
148.3B USD
Loading...
FR
Sanofi SA
PAR:SAN
93.8B EUR
Loading...

Market Distribution

Higher than 79% of companies in Italy
Percentile
79th
Based on 1 294 companies
79th percentile
16.4%
Low
-24 712% — 1.6%
Typical Range
1.6% — 10.1%
High
10.1% — 3 667.8%
Distribution Statistics
Italy
Min -24 712%
30th Percentile 1.6%
Median 5.3%
70th Percentile 10.1%
Max 3 667.8%

Recordati Industria Chimica e Farmaceutica SpA
Glance View

Nestled within the vibrant landscape of the Italian pharmaceutical industry, Recordati Industria Chimica e Farmaceutica SpA has carved a distinct identity over its nearly century-long journey. Founded in 1926 by Giovanni Recordati, the company has evolved from a small chemical laboratory into one of Europe's prominent players in pharmaceuticals. The heart of Recordati's operations lies in its robust portfolio, which spans pharmaceuticals, rare disease treatments, and consumer health products. With a commitment to innovation and diligent R&D efforts, Recordati continuously develops both proprietary drugs and generic medicines, ensuring a diverse revenue stream. Aiming to address crucial health challenges, the company has strategically expanded its rare disease segment, exploring niche markets with high unmet medical needs. Recordati's business model is a sophisticated blend of internal development, strategic acquisitions, and partnerships. The company's success largely hinges on its ability to identify and integrate complementary businesses, enhancing its global footprint. Through a network covering Western Europe, Central and Eastern Europe, as well as North America and emerging markets, Recordati not only distributes its own line of medications but also collaborates with other pharmaceutical entities to commercialize their products. This strategic expansion, coupled with a proactive approach to fostering market-specific adaptations, supports a steady flow of revenue. Revenue sustainability is further bolstered by a responsive supply chain and targeted marketing strategies that strengthen Recordati's competitive stance in the pharmaceutical sector worldwide.

REC Intrinsic Value
HIDDEN
Show
What is Net Margin?
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
How is Net Margin calculated?

Net Margin is calculated by dividing the Net Income by the Revenue.

Net Margin
16.4%
=
Net Income
€407.3m
/
Revenue
€2.5B
What is Recordati Industria Chimica e Farmaceutica SpA's current Net Margin?

The current Net Margin for Recordati Industria Chimica e Farmaceutica SpA is 16.4%, which is below its 3-year median of 17.8%.

How has Net Margin changed over time?

Over the last 3 years, Recordati Industria Chimica e Farmaceutica SpA’s Net Margin has decreased from 19.4% to 16.4%. During this period, it reached a low of 16.4% on Jun 30, 2025 and a high of 19.4% on Jun 30, 2022.

Back to Top